INSC Variant 1: A Potential Drug Target Or Biomarker (G387755)

Target Name: INSC

NCBI ID: G387755

INSC

INSC Variant 1: A Potential Drug Target Or Biomarker

INSC (IN squirrel) is a novel biomarker caused by INSC variant 1, a genetic mutation. The findings suggest that INSC variant 1 may be a potential drug target or biomarker. This article will describe the basic information, characteristics and possible drug targets or biomarkers of INSC variant 1.

Basic Information

INSC variant 1 is a genetic mutation that occurs in the coding region of the INSC gene. The protein encoded by this gene is a glycoprotein also known as an integrin receptor. Glycoproteins are complexes composed of two sugar molecules and protein molecules. They have broad application prospects in the fields of cell signaling, tissue engineering, and regenerative medicine.

feature

INSC variant 1 has the following characteristics:

1. Changes in expression pattern: INSC variant 1 causes changes in the expression pattern of INSC genes. The study found that the INSC variant 1 gene expressed a reduced amount of protein and an increased amount of expressed glycoprotein.

2. Cell adhesion: INSC variant 1 causes the weakening of INSC cell cell adhesion. Cell adhesion is an important process of cell-tissue interaction, which is closely related to processes such as cell proliferation, tissue repair and regeneration.

3. Morphological changes: INSC variant 1 causes changes in the morphological structure of INSC cells. Specifically, INSC variant 1 cells became thinner, longer, more uniform, and had a different shape.

4. Functional studies: Studies have shown that the protein encoded by INSC variant 1 has the effect of inhibiting vascular endothelial growth factor (VEGF). VEGF is an important factor that promotes blood vessel growth and cancer cell invasion. Inhibition of VEGF may have antitumor and antiangiogenic effects.

drug target or biomarker

INSC variant 1 may be a potential drug target or biomarker because it encodes a protein that inhibits vascular endothelial growth factor (VEGF). VEGF is an important factor that promotes blood vessel growth and cancer cell invasion. Inhibition of VEGF may have antitumor and antiangiogenic effects.

In addition, INSC variant 1 may also be a biomarker for assessing disease status and treatment response in patients. For example, by measuring the expression levels of INSC variant 1, patients' disease severity and treatment response can be assessed.

in conclusion

In summary, INSC variant 1 is a potential drug target or biomarker. By inhibiting vascular endothelial growth factor (VEGF), INSC variant 1 may have anti-tumor and anti-angiogenic effects. In addition, INSC variant 1 may also be a biomarker for assessing disease status and treatment response in patients. Therefore, it is important to study the biological and clinical significance of INSC variant 1.

Protein Name: INSC Spindle Orientation Adaptor Protein

Functions: May function as an adapter linking the Par3 complex to the GPSM1/GPSM2 complex (PubMed:16458856). Involved in spindle orientation during mitosis. May regulate cell proliferation and differentiation in the developing nervous system. May play a role in the asymmetric division of fibroblasts and participate in the process of stratification of the squamous epithelium (By similarity)

The "INSC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INSC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets